Accordingly, several DPP4 inhibitors such as sitagliptin are approved for the management of type 2 diabetes, as DPP4 inhibition in this context prolongs the half-life of GLP1 and GIP, increasing endogenous insulin secretion [15]. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.